The two drug companies added, on Thursday, that an analysis of the blood serum of thirty participants of children who received a booster dose in the framework of a study, showed an increase of the neutralizing antibodies to Omicron by 36 times.
Neutralizing antibodies resistant to the original version of the virus for which the vaccine was designed increased sixfold after the booster dose.
The two companies stated that they intend to file an application for authorization for emergency use of the booster dose for that age group in the United States in the coming days, to be followed by additional applications to global regulators such as the European Medicines Agency.
According to data from the US Centers for Disease Control and Prevention, only 28 percent of children in this age group, about eight million children, have been fully vaccinated.
Health experts described the data as “promising” but cautioned that the size of the study was too small, and said more data was needed to understand to what extent the booster dose prevents severe symptoms of Covid-19 or prevents children from needing to be hospitalized, and also its ability. To face the mutations that may appear in the future.
This year, the US Food and Drug Administration allowed a third dose of the vaccine for children aged 12 to 15 years, as well as those aged 5 to 11 years who are immunocompromised.
#Pfizer #Booster #Dose #Increases #Child #Protection #Omicron